首页 > 最新文献

Chinese Medical Sciences Journal最新文献

英文 中文
Cuproptosis-Related 4-Gene Risk Model for Predicting Immunotherapy Drug Response and Prognosis of Kidney Renal Clear Cell Carcinoma [用于预测肾透明细胞癌的免疫治疗药物反应和预后的杯状相关4基因风险模型]。
Q2 Medicine Pub Date : 2023-09-01 DOI: 10.24920/004223
Jin-Shuai Guo , Hao Ding , Peng-Yu Wu , Zi-Yi Xin , Jian-Xin Li , Hyon-Su Jo , Zhen-Hai Ma

Background

Kidney renal clear cell carcinoma (KIRC) is one of the most common renal malignancies with a high mortality rate. Cuproptosis, a novel form of cell death, is strongly linked to mitochondrial metabolism and is mediated by protein lipoylation, leading to a proteotoxic stress response and cell death. To date, few studies have ellucidated the holistic role of cuproptosis-related genes (CRGs) in the pathogenesis of KIRC.

Methods

We comprehensively and completely analyzed the RNA sequencing data and corresponding clinical information from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. We screened for differentially expressed CRGs and constructed a prognostic risk model using univariate and multivariate Cox proportional regression analyses. Kaplan-Meier analysis was performed and receiver operating characteristic (ROC) curves were plotted to predict the prognosis of KIRC patients. Functional enrichment analysis was utilized to explore the internal mechanisms. Immune-related functions were analyzed using single-sample gene set enrichment analysis (ssGSEA), tumour immune dysfunction and exclusion (TIDE) scores, and drug sensitivity analysis.

Results

We established a concise prognostic risk model consisting of four CRGs (DBT, DLAT, LIAS and PDHB) to predict the overall survival (OS) in KIRC patients. The results of the survival analysis indicated a significantly lower OS in the high-risk group as compared to the patients in the low-risk group. The area under the time-dependent ROC curve (AUC) at 1, 3, and 5 year was 0.691, 0.618, and 0.614 in KIRC. Functional enrichment analysis demonstrated that CRGs were significantly enriched in tricarboxylic acid (TCA) cycle-related processes and metabolism-related pathways. Sorafenib, doxorubicin, embelin, and vinorelbine were more sensitive in the high-risk group.

Conclusions

We constructed a concise CRGs risk model to evaluate the prognosis of KIRC patients and this may be a new direction for the diagnosis and treatment of KIRC.

背景肾脏透明细胞癌(KIRC)是最常见的肾脏恶性肿瘤之一,死亡率很高。杯状细胞病是一种新型的细胞死亡,与线粒体代谢密切相关,并由蛋白质脂质化介导,导致蛋白毒性应激反应和细胞死亡。到目前为止,很少有研究阐明铜中毒相关基因(CRG)在KIRC发病机制中的整体作用。方法对癌症基因组图谱(TCGA)和基因表达综合数据库(GEO)的RNA测序数据和相应的临床信息进行全面、完整的分析。我们筛选了差异表达的CRG,并使用单变量和多变量Cox比例回归分析构建了预后风险模型。进行Kaplan-Meier分析,绘制受试者操作特征(ROC)曲线以预测KIRC患者的预后。利用功能富集分析来探索其内在机制。使用单样本基因集富集分析(ssGSEA)、肿瘤免疫功能障碍和排除(TIDE)评分和药物敏感性分析分析免疫相关功能。结果我们建立了一个由四种CRG(DBT、DLAT、LIAS和PDHB)组成的简明预后风险模型来预测KIRC患者的总生存期(OS)。生存分析的结果表明,与低风险组的患者相比,高风险组的OS显著降低。KIRC在1年、3年和5年的时间依赖性ROC曲线下面积分别为0.691、0.618和0.614。功能富集分析表明,CRG在三羧酸(TCA)循环相关过程和代谢相关途径中显著富集。索拉非尼、阿霉素、恩贝林和长春瑞滨在高危人群中更敏感。结论我们构建了一个简明的CRGs风险模型来评估KIRC患者的预后,这可能是诊断和治疗KIRC的一个新方向。
{"title":"Cuproptosis-Related 4-Gene Risk Model for Predicting Immunotherapy Drug Response and Prognosis of Kidney Renal Clear Cell Carcinoma","authors":"Jin-Shuai Guo ,&nbsp;Hao Ding ,&nbsp;Peng-Yu Wu ,&nbsp;Zi-Yi Xin ,&nbsp;Jian-Xin Li ,&nbsp;Hyon-Su Jo ,&nbsp;Zhen-Hai Ma","doi":"10.24920/004223","DOIUrl":"10.24920/004223","url":null,"abstract":"<div><h3>Background</h3><p>Kidney renal clear cell carcinoma (KIRC) is one of the most common renal malignancies with a high mortality rate. Cuproptosis, a novel form of cell death, is strongly linked to mitochondrial metabolism and is mediated by protein lipoylation, leading to a proteotoxic stress response and cell death. To date, few studies have ellucidated the holistic role of cuproptosis-related genes (CRGs) in the pathogenesis of KIRC.</p></div><div><h3>Methods</h3><p>We comprehensively and completely analyzed the RNA sequencing data and corresponding clinical information from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. We screened for differentially expressed CRGs and constructed a prognostic risk model using univariate and multivariate Cox proportional regression analyses. Kaplan-Meier analysis was performed and receiver operating characteristic (ROC) curves were plotted to predict the prognosis of KIRC patients. Functional enrichment analysis was utilized to explore the internal mechanisms. Immune-related functions were analyzed using single-sample gene set enrichment analysis (ssGSEA), tumour immune dysfunction and exclusion (TIDE) scores, and drug sensitivity analysis.</p></div><div><h3>Results</h3><p>We established a concise prognostic risk model consisting of four CRGs (DBT, DLAT, LIAS and PDHB) to predict the overall survival (OS) in KIRC patients. The results of the survival analysis indicated a significantly lower OS in the high-risk group as compared to the patients in the low-risk group. The area under the time-dependent ROC curve (AUC) at 1, 3, and 5 year was 0.691, 0.618, and 0.614 in KIRC. Functional enrichment analysis demonstrated that CRGs were significantly enriched in tricarboxylic acid (TCA) cycle-related processes and metabolism-related pathways. Sorafenib, doxorubicin, embelin, and vinorelbine were more sensitive in the high-risk group.</p></div><div><h3>Conclusions</h3><p>We constructed a concise CRGs risk model to evaluate the prognosis of KIRC patients and this may be a new direction for the diagnosis and treatment of KIRC.</p></div>","PeriodicalId":35615,"journal":{"name":"Chinese Medical Sciences Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9881309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Associations of Oxalate Consumption and Some Individual Habits with the Risk of Kidney Stones [草酸盐消费和某些个人习惯与肾结石风险的关系]。
Q2 Medicine Pub Date : 2023-09-01 DOI: 10.24920/004207
Nahid Zainodini , Periklis Dousdampanis , Zahra Ahmadi , Maryam Mohamadi , Alireza Nazari

Kidney stone is a highly recurrent disease in the urinary tract system. Most kidney stones are calcium stones, usually consisting of either calcium oxalate or calcium phosphate. Supersaturation of soluble calcium, oxalate, phosphate, and citrate in the urine is the basis for calcium stone formation. Genetics, diet, low physical activity, and individual habits contribute to the formation of kidney stones. In this review, the associations of the risk of kidney stones with oxalate consumption and some individual habits, such as smoking, alcohol drinking, and opium consumption, are summarized.

肾结石是泌尿系统中一种高度复发的疾病。大多数肾结石是钙结石,通常由草酸钙或磷酸钙组成。尿液中可溶性钙、草酸盐、磷酸盐和柠檬酸盐的过饱和是钙结石形成的基础。遗传、饮食、低体力活动和个人习惯有助于肾结石的形成。在这篇综述中,总结了肾结石风险与草酸盐消费和一些个人习惯(如吸烟、饮酒和鸦片消费)的关系。
{"title":"Associations of Oxalate Consumption and Some Individual Habits with the Risk of Kidney Stones","authors":"Nahid Zainodini ,&nbsp;Periklis Dousdampanis ,&nbsp;Zahra Ahmadi ,&nbsp;Maryam Mohamadi ,&nbsp;Alireza Nazari","doi":"10.24920/004207","DOIUrl":"10.24920/004207","url":null,"abstract":"<div><p>Kidney stone is a highly recurrent disease in the urinary tract system. Most kidney stones are calcium stones, usually consisting of either calcium oxalate or calcium phosphate. Supersaturation of soluble calcium, oxalate, phosphate, and citrate in the urine is the basis for calcium stone formation. Genetics, diet, low physical activity, and individual habits contribute to the formation of kidney stones. In this review, the associations of the risk of kidney stones with oxalate consumption and some individual habits, such as smoking, alcohol drinking, and opium consumption, are summarized.</p></div>","PeriodicalId":35615,"journal":{"name":"Chinese Medical Sciences Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10467764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blood Pressure Variability May Be a New Predictor for the Occurrence and Prognosis of Ischemic Stroke [血压变异性可能是缺血性卒中发生和预后的新预测因素]。
Q2 Medicine Pub Date : 2023-09-01 DOI: 10.24920/004219
Ke-Qiong Yan, Qi-Si Wu, Jun Yang

Despite declines in morbidity and mortality in recent years, ischemic stroke (IS) remains one of the leading causes of death and disability from cerebrovascular diseases. Addressing the controllable risk factors underpins the successful clinical management of IS. Hypertension is one of the most common treatable risk factors for IS and is associated with poor outcomes. Ambulatory blood pressure monitoring has revealed that patients with hypertension have a higher incidence of blood pressure variability (BPV) than those without hypertension. Meanwhile, increased BPV has been identified as a risk factor for IS. The risk of IS is higher and the prognosis after infarction is worse with higher BPV, no matter in the acute or subacute phase. BPV is multifactorial, with alterations reflecting individual physiological and pathological changes. This article reviews the current research advances in the relationship between BPV and IS, with an attempt to raise awareness of BPV among clinicians and IS patients, explore the increased BPV as a controllable risk factor for IS, and encourage hypertensive patients to control not only average blood pressure but also BPV and implement personalized blood pressure management.

尽管近年来发病率和死亡率有所下降,但缺血性中风(IS)仍然是脑血管疾病死亡和致残的主要原因之一。解决可控的风险因素是IS成功临床管理的基础。高血压是IS最常见的可治疗风险因素之一,与不良预后有关。动态血压监测显示,高血压患者的血压变异性(BPV)发生率高于非高血压患者。同时,BPV升高已被确定为IS的危险因素。无论是在急性期还是亚急性期,BPV越高,IS的风险越高,梗死后的预后越差。BPV是多因素的,其改变反映了个体的生理和病理变化。本文综述了目前BPV与IS关系的研究进展,旨在提高临床医生和IS患者对BPV的认识,探讨BPV升高是IS的可控危险因素,鼓励高血压患者不仅控制平均血压,而且控制BPV,实施个性化血压管理。
{"title":"Blood Pressure Variability May Be a New Predictor for the Occurrence and Prognosis of Ischemic Stroke","authors":"Ke-Qiong Yan,&nbsp;Qi-Si Wu,&nbsp;Jun Yang","doi":"10.24920/004219","DOIUrl":"10.24920/004219","url":null,"abstract":"<div><p>Despite declines in morbidity and mortality in recent years, ischemic stroke (IS) remains one of the leading causes of death and disability from cerebrovascular diseases. Addressing the controllable risk factors underpins the successful clinical management of IS. Hypertension is one of the most common treatable risk factors for IS and is associated with poor outcomes. Ambulatory blood pressure monitoring has revealed that patients with hypertension have a higher incidence of blood pressure variability (BPV) than those without hypertension. Meanwhile, increased BPV has been identified as a risk factor for IS. The risk of IS is higher and the prognosis after infarction is worse with higher BPV, no matter in the acute or subacute phase. BPV is multifactorial, with alterations reflecting individual physiological and pathological changes. This article reviews the current research advances in the relationship between BPV and IS, with an attempt to raise awareness of BPV among clinicians and IS patients, explore the increased BPV as a controllable risk factor for IS, and encourage hypertensive patients to control not only average blood pressure but also BPV and implement personalized blood pressure management.</p></div>","PeriodicalId":35615,"journal":{"name":"Chinese Medical Sciences Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9593128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Chinese Herb Prescription “Fang-gan Decoction” Protects Against Damage to Lung and Colon Epithelial Cells Caused by the SARS-CoV-2 Spike Protein by Regulating the TGF-β/Smad2/3 and NF-κB Pathways 【中药方肝汤通过调节TGF-β/Smad2/3和NF-κB通路保护严重急性呼吸系统综合征冠状病毒2型刺突蛋白对肺和结肠上皮细胞的损伤】。
Q2 Medicine Pub Date : 2023-09-01 DOI: 10.24920/004198
Chao Huang, Hao-Sheng Liu, Bing-Jun Liang, Sheng-Rong Liao, Wei-Zeng Shen

Objective

To explore the effects and mechanisms of a traditional Chinese medicine (TCM) prescription, “Fang-gan Decoction” (FGD), in protecting against SARS-CoV-2 spike protein-induced lung and intestinal injuries in vitro and in vivo.

Methods

Female BALB/c mice and three cell lines pretreated with FGD were stimulated with recombinant SARS-CoV-2 spike protein (spike protein). Hematoxylineosin (HE) staining and pathologic scoring of tissues, cell permeability and viability, and angiotensin-converting enzyme 2 (ACE2) expression in the lung and colon were detected. Enzyme-linked immunosorbent assay (ELISA) was performed to detect the levels of inflammatory factors in serum and cell supernatant. The expression of NF-κB p65, p-NF-κB p6S, p-IκBα, p-Smad2/3, TGF-β1, Caspase3, and Bel-2 was evaluated by Western blotting.

Results

FGD protected against the damage to the lung and colon caused by the spike protein in vivo and in vitro according to the pathologic score and cell permeability and viability (P<0.05). FGD up-regulated ACE2 expression, which was reduced by the spike protein in the lung and colon, significantly improved the deregulation of inflammatory markers caused by the spike protein, and regulated the activity of TGF-β/Smads and NF-κB signaling.

Conclusion

Traditional Chinese medicine has a protective effect on lung and intestinal tissue injury stimulated by the spike protein through possible regulatory functions of the NF-κB and TGF-β1/Smad pathways with tissue type specificity.

目的探讨方肝汤对严重急性呼吸系统综合征冠状病毒2型刺突蛋白所致肺、肠损伤的保护作用及其机制。方法用重组严重急性呼吸系统综合征冠状病毒2型刺突蛋白刺激雌性BALB/c小鼠和三种经FGD预处理的细胞系。检测肺和结肠中组织的苏木精-伊红(HE)染色和病理评分、细胞通透性和活力以及血管紧张素转换酶2(ACE2)的表达。酶联免疫吸附试验(ELISA)检测血清和细胞上清液中炎症因子的水平。通过蛋白质印迹法评估NF-κB p65、p-NF-κBp65、p-IκBα、p-Smad2/3、TGF-β1、Caspase3和Bcl-2的表达。结果从病理评分、细胞通透性和生存能力来看,FGD在体内外均能保护肺和结肠免受刺突蛋白的损伤(P
{"title":"A Chinese Herb Prescription “Fang-gan Decoction” Protects Against Damage to Lung and Colon Epithelial Cells Caused by the SARS-CoV-2 Spike Protein by Regulating the TGF-β/Smad2/3 and NF-κB Pathways","authors":"Chao Huang,&nbsp;Hao-Sheng Liu,&nbsp;Bing-Jun Liang,&nbsp;Sheng-Rong Liao,&nbsp;Wei-Zeng Shen","doi":"10.24920/004198","DOIUrl":"10.24920/004198","url":null,"abstract":"<div><h3>Objective</h3><p>To explore the effects and mechanisms of a traditional Chinese medicine (TCM) prescription, “<em>Fang-gan</em> Decoction” (FGD), in protecting against SARS-CoV-2 spike protein-induced lung and intestinal injuries in <em>vitro</em> and in <em>vivo.</em></p></div><div><h3>Methods</h3><p>Female BALB/c mice and three cell lines pretreated with FGD were stimulated with recombinant SARS-CoV-2 spike protein (spike protein). Hematoxylineosin (HE) staining and pathologic scoring of tissues, cell permeability and viability, and angiotensin-converting enzyme 2 (ACE2) expression in the lung and colon were detected. Enzyme-linked immunosorbent assay (ELISA) was performed to detect the levels of inflammatory factors in serum and cell supernatant. The expression of NF-κB p65, p-NF-κB p6S, p-IκBα, p-Smad2/3, TGF-β1, Caspase3, and Bel-2 was evaluated by Western blotting.</p></div><div><h3>Results</h3><p>FGD protected against the damage to the lung and colon caused by the spike protein in <em>vivo</em> and in <em>vitro</em> according to the pathologic score and cell permeability and viability (<em>P</em>&lt;0.05). FGD up-regulated ACE2 expression, which was reduced by the spike protein in the lung and colon, significantly improved the deregulation of inflammatory markers caused by the spike protein, and regulated the activity of TGF-β/Smads and NF-κB signaling.</p></div><div><h3>Conclusion</h3><p>Traditional Chinese medicine has a protective effect on lung and intestinal tissue injury stimulated by the spike protein through possible regulatory functions of the NF-κB and TGF-β1/Smad pathways with tissue type specificity.</p></div>","PeriodicalId":35615,"journal":{"name":"Chinese Medical Sciences Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9746815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In-hospital Mortality and Hospital Outcomes among Adults Hospitalized for Exacerbations of Asthma and COPD in Southern Thailand (2017-2021): A Population-Based Study [泰国南部因哮喘和慢性阻塞性肺病加重而住院的成年人的住院死亡率和住院结果(2017-2021):一项基于人群的研究]。
Q2 Medicine Pub Date : 2023-09-01 DOI: 10.24920/004252
Narongwit Nakwan , Kanittha Suansan

Background

Hospitalizations for asthma and chronic obstructive pulmonary disease (COPD) exacerbations frequently occur in Thailand. National trends in hospital outcomes are essential for planning preventive strategies within the healthcare system. We examined temporal trends in in-hospital outcomes, including mortality rate, length of stay (LOS), and expenses for reimbursement in adults hospitalized for asthma and COPD exacerbations in southern Thailand.

Methods

A retrospective, population-based study on adults hospitalized for exacerbations of asthma and COPD was carried out using data from the National Health Security Office in southern Thailand. Baseline demographic and in-hospital outcome assessments were conducted on 19,459 and 66,457 hospitalizations for asthma and COPD, respectively, between 2017 and 2021.

Results

Significant reductions in hospital admissions for exacerbations of asthma and COPD were observed over time, particularly in 2020/2021. From 2017 to 2021, the in-hospital mortality rate for asthma rose from 3.2 to 3.7 deaths per 1,000 admissions (P<0.05). The rates for COPD admissions, on the other hand, reduced from 20.3 to 16.4 deaths per 1,000 admissions between 2017 and 2020, but subsequently increased to 21.8 in 2021 (P<0.05). The prominent contributor to the higher mortality rate was found to be increasing age. Nonetheless, the average LOS for both asthma and COPD decreased slightly over the study period. The total expenses for reimbursing exacerbations of asthma and COPD per hospitalisation have risen significantly each year, with a particularly notable increase in 2020/2021.

Conclusion

During 2017-2021, exacerbations of asthma and COPD in Thailand continued to account for significant in-hospital mortality rates and reimbursement expenses, despite the overall decrease in hospitalizations and slight fluctuations in the LOS.

背景泰国经常发生哮喘和慢性阻塞性肺病(COPD)加重的住院治疗。全国医院结果的趋势对于在医疗保健系统内规划预防策略至关重要。我们研究了泰国南部因哮喘和慢性阻塞性肺病恶化住院的成年人的住院结果的时间趋势,包括死亡率、住院时间(LOS)和报销费用。方法利用泰国南部国家卫生安全办公室的数据,对因哮喘和慢性阻塞性肺病恶化而住院的成年人进行了一项基于人群的回顾性研究。2017年至2021年间,分别对19459例和66457例哮喘和慢性阻塞性肺病住院患者进行了基线人口统计和住院结果评估。结果随着时间的推移,尤其是在2020/2021年,哮喘和慢性阻肺恶化的住院人数显著减少。从2017年到2021年,哮喘的住院死亡率从每1000名住院患者3.2例上升到3.7例(P
{"title":"In-hospital Mortality and Hospital Outcomes among Adults Hospitalized for Exacerbations of Asthma and COPD in Southern Thailand (2017-2021): A Population-Based Study","authors":"Narongwit Nakwan ,&nbsp;Kanittha Suansan","doi":"10.24920/004252","DOIUrl":"10.24920/004252","url":null,"abstract":"<div><h3>Background</h3><p>Hospitalizations for asthma and chronic obstructive pulmonary disease (COPD) exacerbations frequently occur in Thailand. National trends in hospital outcomes are essential for planning preventive strategies within the healthcare system. We examined temporal trends in in-hospital outcomes, including mortality rate, length of stay (LOS), and expenses for reimbursement in adults hospitalized for asthma and COPD exacerbations in southern Thailand.</p></div><div><h3>Methods</h3><p>A retrospective, population-based study on adults hospitalized for exacerbations of asthma and COPD was carried out using data from the National Health Security Office in southern Thailand. Baseline demographic and in-hospital outcome assessments were conducted on 19,459 and 66,457 hospitalizations for asthma and COPD, respectively, between 2017 and 2021.</p></div><div><h3>Results</h3><p>Significant reductions in hospital admissions for exacerbations of asthma and COPD were observed over time, particularly in 2020/2021. From 2017 to 2021, the in-hospital mortality rate for asthma rose from 3.2 to 3.7 deaths per 1,000 admissions (<em>P</em>&lt;0.05). The rates for COPD admissions, on the other hand, reduced from 20.3 to 16.4 deaths per 1,000 admissions between 2017 and 2020, but subsequently increased to 21.8 in 2021 (<em>P</em>&lt;0.05). The prominent contributor to the higher mortality rate was found to be increasing age. Nonetheless, the average LOS for both asthma and COPD decreased slightly over the study period. The total expenses for reimbursing exacerbations of asthma and COPD per hospitalisation have risen significantly each year, with a particularly notable increase in 2020/2021.</p></div><div><h3>Conclusion</h3><p>During 2017-2021, exacerbations of asthma and COPD in Thailand continued to account for significant in-hospital mortality rates and reimbursement expenses, despite the overall decrease in hospitalizations and slight fluctuations in the LOS.</p></div>","PeriodicalId":35615,"journal":{"name":"Chinese Medical Sciences Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10144002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Dataset on the Dynamic Monitoring of Health and Family Planning of China’s Internal Migrants: A Multi-Wave Large-Scale, National Cross-Sectional Survey from 2009 to 2018 【中国境内流动人口健康和计划生育动态监测数据集:2009年至2018年多波大规模全国横断面调查】。
Q2 Medicine Pub Date : 2023-09-01 DOI: 10.24920/004254
Sheng-Fa Zhang , Wei Luo , Zhi-Li Wang , Jing Chen , Fang Zhou , Jing-Wen Sun , Jia-Yang Wang , Jing-Chen Zhang , Wei Zhou

This data article presents data from the China Migrants Dynamic Survey (CMDS), a multi-wave, large-scale national cross-sectional survey of China’s internal migrants from 2009 to 2018. The CMDS is an annual questionnaire survey conducted by the former National Health and Family Planning Commission (NHFPC) of the People’s Republic of China. The respondents included in this survey are internal migrants over IS years old. The sample was drawn from the China Migrant Population Information System, using multi-stage stratified sampling method and the probability proportional-to-size (PPS) cluster sampling strategy. Between 2009 and 2018, there were 1,527,650 internal migrants from 23 provinces, 5 autonomous regions and 4 municipalities participated in the surveys. The survey tools were a series of self-designed questionnaires with high inheritance and consistency designed and implemented by the NHFPC. The questionnaires mainly contain basic information of the respondents and their family members, migration status, healthcare or health behaviors, public health service utilization, social insurance, social integration, and family planning. The dataset is currently the most widely used survey data on China’s internal migrants, offering information on migration patterns, healthcare and health behaviors, use of public health services, access to social security, social integration, and family planning, which are valuable for health planning, health decision-making, and health equity research.

这篇数据文章介绍了中国移民动态调查(CMDS)的数据,这是一项针对2009年至2018年中国国内移民的多波大规模全国性横断面调查。CMDS是由中华人民共和国前国家卫生和计划生育委员会(NHFPC)进行的年度问卷调查。本次调查的受访者是15岁以上的国内移民。样本来源于中国流动人口信息系统,采用多阶段分层抽样方法和PPS整群抽样策略。2009年至2018年间,共有来自23个省、5个自治区和4个直辖市的1527650名境内移民参加了调查。调查工具是由NHFPC设计和实施的一系列自行设计的具有高度继承性和一致性的问卷。调查问卷主要包括受访者及其家庭成员的基本信息、移民状况、医疗保健或健康行为、公共卫生服务利用、社会保险、社会融合和计划生育。该数据集是目前使用最广泛的中国境内移民调查数据,提供了移民模式、医疗保健和健康行为、公共卫生服务使用、社会保障、社会融合和计划生育等信息,对健康规划、健康决策和健康公平研究有价值。
{"title":"A Dataset on the Dynamic Monitoring of Health and Family Planning of China’s Internal Migrants: A Multi-Wave Large-Scale, National Cross-Sectional Survey from 2009 to 2018","authors":"Sheng-Fa Zhang ,&nbsp;Wei Luo ,&nbsp;Zhi-Li Wang ,&nbsp;Jing Chen ,&nbsp;Fang Zhou ,&nbsp;Jing-Wen Sun ,&nbsp;Jia-Yang Wang ,&nbsp;Jing-Chen Zhang ,&nbsp;Wei Zhou","doi":"10.24920/004254","DOIUrl":"10.24920/004254","url":null,"abstract":"<div><p>This data article presents data from the China Migrants Dynamic Survey (CMDS), a multi-wave, large-scale national cross-sectional survey of China’s internal migrants from 2009 to 2018. The CMDS is an annual questionnaire survey conducted by the former National Health and Family Planning Commission (NHFPC) of the People’s Republic of China. The respondents included in this survey are internal migrants over IS years old. The sample was drawn from the China Migrant Population Information System, using multi-stage stratified sampling method and the probability proportional-to-size (PPS) cluster sampling strategy. Between 2009 and 2018, there were 1,527,650 internal migrants from 23 provinces, 5 autonomous regions and 4 municipalities participated in the surveys. The survey tools were a series of self-designed questionnaires with high inheritance and consistency designed and implemented by the NHFPC. The questionnaires mainly contain basic information of the respondents and their family members, migration status, healthcare or health behaviors, public health service utilization, social insurance, social integration, and family planning. The dataset is currently the most widely used survey data on China’s internal migrants, offering information on migration patterns, healthcare and health behaviors, use of public health services, access to social security, social integration, and family planning, which are valuable for health planning, health decision-making, and health equity research.</p></div>","PeriodicalId":35615,"journal":{"name":"Chinese Medical Sciences Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10167622","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Expert Consensus on Acute Respiratory Failure in Critically III Cancer Patients (2023) 危重III级癌症患者急性呼吸衰竭专家共识(2023)
Q2 Medicine Pub Date : 2023-09-01 DOI: 10.24920/004203
Hai-Jun Wang , Wei Chen , Hong-Zhi Wang , He-Ling Zhao , Dong-Hao Wang , Yun Long , Xue-Zhong Xing , on behalf of the Critical Care Medicine Committee of Beijing Association of Oncology (CCMBAO)

Objective

This consensus aims to provide evidence-based recommendations on common questions in the diagnosis and treatment of acute respiratory failure (ARF) for critically ill cancer patients.

Methods

We developed six clinical questions using the PICO (Population, Intervention, Comparison, and Outcome) principle in diagnosis and treatment for critical ill cancer patients with ARF. Based on literature searching and meta-analyses, recommendations were devised. The GRADE (Grading of Recommendation Assessment, Development and Evaluation) method was applied to each question to reach consensus in the expert panel.

Results

The panel makes strong recommendations in favor of (1) metagenomic next-generation sequencing (mNGS) tests may aid clinicians in rapid diagnosis in critically ill cancer patients suspected of pulmonary infections; (2) extracorporeal membrane oxygenation (ECMO) therapy should not be used as a routine rescue therapy for acute respiratory distress syndrome in critically ill cancer patients but may benefit highly selected patients after multi-disciplinary consultations; (3) cancer patients who have received immune checkpoint inhibitor therapy have an increased incidence of pneumonitis compared with standard chemotherapy; (4) critically ill cancer patients who are on invasive mechanical ventilation and estimated to be extubated after 14 days may benefit from early tracheotomy; and (5) high-flow nasal oxygen and noninvasive ventilation therapy can be used as a first-line oxygen strategy for critically ill cancer patients with ARFs. A weak recommendation is: (6) for critically ill cancer patients with ARF caused by tumor compression, urgent chemotherapy may be considered as a rescue therapy only in patients determined to be potentially sensitive to the anticancer therapy after multidisciplinary consultations.

Conclusions

The recommendations based on the available evidence can guide diagnosis and treatment in critically ill cancer patients with acute respiratory failure and improve outcomes.

目的本共识旨在为危重癌症患者急性呼吸衰竭(ARF)的诊断和治疗中的常见问题提供循证建议。方法应用PICO(群体、干预、比较和结果)原则对危重癌症ARF患者进行诊断和治疗,提出6个临床问题。在文献检索和荟萃分析的基础上,提出了建议。将GRADE(推荐评估、发展和评估分级)方法应用于每个问题,以在专家小组中达成共识。结果该小组强烈建议:(1)宏基因组下一代测序(mNGS)测试可能有助于临床医生对怀疑肺部感染的危重癌症患者进行快速诊断;(2) 体外膜肺氧合(ECMO)治疗不应作为危重癌症患者急性呼吸窘迫综合征的常规抢救治疗,但可在多学科会诊后使高度选择的患者受益;(3) 与标准化疗相比,接受免疫检查点抑制剂治疗的癌症患者肺炎发病率增加;(4) 正在接受有创机械通气并估计14天后拔管的癌症危重患者可能受益于早期气管切开术;(5)高流量鼻氧和无创通气治疗可作为危重癌症ARF患者的一线氧气策略。一个较弱的建议是:(6)对于因肿瘤压迫引起的危重癌症ARF患者,只有在多学科咨询后确定对抗癌治疗潜在敏感的患者,才可以考虑将紧急化疗作为抢救性治疗。结论根据现有证据提出的建议可指导危重癌症急性呼吸衰竭患者的诊断和治疗,改善预后。
{"title":"Expert Consensus on Acute Respiratory Failure in Critically III Cancer Patients (2023)","authors":"Hai-Jun Wang ,&nbsp;Wei Chen ,&nbsp;Hong-Zhi Wang ,&nbsp;He-Ling Zhao ,&nbsp;Dong-Hao Wang ,&nbsp;Yun Long ,&nbsp;Xue-Zhong Xing ,&nbsp;on behalf of the Critical Care Medicine Committee of Beijing Association of Oncology (CCMBAO)","doi":"10.24920/004203","DOIUrl":"https://doi.org/10.24920/004203","url":null,"abstract":"<div><h3>Objective</h3><p>This consensus aims to provide evidence-based recommendations on common questions in the diagnosis and treatment of acute respiratory failure (ARF) for critically ill cancer patients.</p></div><div><h3>Methods</h3><p>We developed six clinical questions using the PICO (Population, Intervention, Comparison, and Outcome) principle in diagnosis and treatment for critical ill cancer patients with ARF. Based on literature searching and meta-analyses, recommendations were devised. The GRADE (Grading of Recommendation Assessment, Development and Evaluation) method was applied to each question to reach consensus in the expert panel.</p></div><div><h3>Results</h3><p>The panel makes strong recommendations in favor of (1) metagenomic next-generation sequencing (mNGS) tests may aid clinicians in rapid diagnosis in critically ill cancer patients suspected of pulmonary infections; (2) extracorporeal membrane oxygenation (ECMO) therapy should not be used as a routine rescue therapy for acute respiratory distress syndrome in critically ill cancer patients but may benefit highly selected patients after multi-disciplinary consultations; (3) cancer patients who have received immune checkpoint inhibitor therapy have an increased incidence of pneumonitis compared with standard chemotherapy; (4) critically ill cancer patients who are on invasive mechanical ventilation and estimated to be extubated after 14 days may benefit from early tracheotomy; and (5) high-flow nasal oxygen and noninvasive ventilation therapy can be used as a first-line oxygen strategy for critically ill cancer patients with ARFs. A weak recommendation is: (6) for critically ill cancer patients with ARF caused by tumor compression, urgent chemotherapy may be considered as a rescue therapy only in patients determined to be potentially sensitive to the anticancer therapy after multidisciplinary consultations.</p></div><div><h3>Conclusions</h3><p>The recommendations based on the available evidence can guide diagnosis and treatment in critically ill cancer patients with acute respiratory failure and improve outcomes.</p></div>","PeriodicalId":35615,"journal":{"name":"Chinese Medical Sciences Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67739985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of Medication Rules of Traditional Chinese Medicine for Malaria Treatment Based on Data Mining 【基于数据挖掘的中医药治疗疟疾用药规律分析】。
Q2 Medicine Pub Date : 2023-09-01 DOI: 10.24920/004214
Wen-Long Guo , Hui-Juan Jiang , Yan-Rong Li , Jin-Long Yang

Objective

To analyze the medication rules of traditional Chinese medicine (TCM) for malaria treatment.

Methods

Statistical analysis was conducted on the basic attributes of TCM drugs with regard to property, therapeutic methods, flavor, and meridian tropism. A complex network of TCM drug associations was constructed. Cluster analysis was applied to obtain the core drugs for malaria treatment. The Apriori algorithm was applied to analyze the association rules of these core drugs.

Results

A total of 3S7 herbs were used 3,194 times in 461 prescriptions for malaria treatment. Radix Glycyrrhizae (

), Rhizoma Pinelliae (
), Radix Bupleuri (
), and Radix Dichroae (
) were the frequently used herbs through supplementing, exterior-releasing, heat-clearing, qi-rectifying, and damp-resolving therapeutic methods. Such herbs had warm, natural, and cold herbal properties; pungent, bitter, and sweet flavors; and spleen, lung, and stomach meridian tropisms. Cluster analysis showed 61 core drugs, including Radix Glycyrrhizae, Rhizoma Pinelliae, Radix Bupleuri, and Radix Scutellariae (
). Apriori association rule analysis yielded 12 binomial rules (herb pairs) and 6 trinomial rules (herb combinations). Radix Bupleuri plus Radix Scutellariae was the core herbal pair for treating malaria. This pair could be combined with Rhizoma Atractylodis Macrocephalae (
) for treating warm or cold malaria, combined with Pericarpium Citri Reticulatae (
) or Radix Dichroae (
) for treating miasmic malaria, or combined with turtle shells (
) for treating malaria with splenomegaly.

Conclusions

TCM can be used to classify and treat malaria in accordance with the different stages of development. As the core herbal pair, Radix Bupleuri and Radix Scutellariae can be combined with other drugs to treat malaria with different syndrome types.

目的分析中医药治疗疟疾的用药规律。方法对中药的性质、治疗方法、味性、归经性等基本属性进行统计分析。构建了一个复杂的中医药协会网络。应用聚类分析获得了治疗疟疾的核心药物。应用Apriori算法对这些核心药物的关联规则进行了分析。结果在461个疟疾治疗处方中,共使用357种中草药3194次。甘草()、山茶()、柴胡()、二胡()是常用的补、表、清热、正气、解湿的中草药。这些草药具有温暖、天然和寒冷的草药特性;辛、苦、甜的味道;以及脾、肺和胃经的斜视。聚类分析显示了61种核心药物,包括甘草、黄连、柴胡和黄芩()。Apriori关联规则分析得到12个二项式规则(草本配对)和6个三项规则(草本组合)。柴胡加黄芩是治疗疟疾的核心药对。本品可与白术()联用治疗温性或寒性疟疾,与陈皮()或地黄()联用药治疗疟疾,或与甲壳类动物()联合用药治疗疟疾伴脾肿大。结论中医药可根据疟疾的不同发展阶段对其进行分类和治疗。柴胡和黄芩作为核心药对,可与其他药物联合治疗不同证型的疟疾。
{"title":"Analysis of Medication Rules of Traditional Chinese Medicine for Malaria Treatment Based on Data Mining","authors":"Wen-Long Guo ,&nbsp;Hui-Juan Jiang ,&nbsp;Yan-Rong Li ,&nbsp;Jin-Long Yang","doi":"10.24920/004214","DOIUrl":"10.24920/004214","url":null,"abstract":"<div><h3>Objective</h3><p>To analyze the medication rules of traditional Chinese medicine (TCM) for malaria treatment.</p></div><div><h3>Methods</h3><p>Statistical analysis was conducted on the basic attributes of TCM drugs with regard to property, therapeutic methods, flavor, and meridian tropism. A complex network of TCM drug associations was constructed. Cluster analysis was applied to obtain the core drugs for malaria treatment. The Apriori algorithm was applied to analyze the association rules of these core drugs.</p></div><div><h3>Results</h3><p>A total of 3S7 herbs were used 3,194 times in 461 prescriptions for malaria treatment. <em>Radix Glycyrrhizae</em> (<figure><img></figure>), <em>Rhizoma Pinelliae</em> (<figure><img></figure>), <em>Radix Bupleuri</em> (<figure><img></figure>), and <em>Radix Dichroae</em> (<figure><img></figure>) were the frequently used herbs through supplementing, exterior-releasing, heat-clearing, qi-rectifying, and damp-resolving therapeutic methods. Such herbs had warm, natural, and cold herbal properties; pungent, bitter, and sweet flavors; and spleen, lung, and stomach meridian tropisms. Cluster analysis showed 61 core drugs, including <em>Radix Glycyrrhizae, Rhizoma Pinelliae, Radix Bupleuri,</em> and <em>Radix Scutellariae</em> (<figure><img></figure>). Apriori association rule analysis yielded 12 binomial rules (herb pairs) and 6 trinomial rules (herb combinations). <em>Radix Bupleuri</em> plus <em>Radix Scutellariae</em> was the core herbal pair for treating malaria. This pair could be combined with <em>Rhizoma Atractylodis Macrocephalae</em> (<figure><img></figure>) for treating warm or cold malaria, combined with <em>Pericarpium Citri Reticulatae</em> (<figure><img></figure>) or <em>Radix Dichroae</em> (<figure><img></figure>) for treating miasmic malaria, or combined with turtle shells (<figure><img></figure>) for treating malaria with splenomegaly.</p></div><div><h3>Conclusions</h3><p>TCM can be used to classify and treat malaria in accordance with the different stages of development. As the core herbal pair, <em>Radix Bupleuri</em> and <em>Radix Scutellariae</em> can be combined with other drugs to treat malaria with different syndrome types.</p></div>","PeriodicalId":35615,"journal":{"name":"Chinese Medical Sciences Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9690740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Strengthening the Disciplinary Construction of History of Medicine: A Call for Action by Chinese Academy of Medical Sciences & Peking Union Medical College 加强医学史学科建设——中国医学科学院和北京协和医学院的行动呼吁
Q2 Medicine Pub Date : 2023-06-01 DOI: 10.24920/004270
Jian-Hong Yao , Da-Qing Zhang , Xin-Zhong Yu , Shu-Jian Zhang , Yong-An Zhang , Xiang-Yin Yang , Zhong He , Huan Liu , Yong Wang , Yue-Ying Jin
{"title":"Strengthening the Disciplinary Construction of History of Medicine: A Call for Action by Chinese Academy of Medical Sciences & Peking Union Medical College","authors":"Jian-Hong Yao ,&nbsp;Da-Qing Zhang ,&nbsp;Xin-Zhong Yu ,&nbsp;Shu-Jian Zhang ,&nbsp;Yong-An Zhang ,&nbsp;Xiang-Yin Yang ,&nbsp;Zhong He ,&nbsp;Huan Liu ,&nbsp;Yong Wang ,&nbsp;Yue-Ying Jin","doi":"10.24920/004270","DOIUrl":"10.24920/004270","url":null,"abstract":"","PeriodicalId":35615,"journal":{"name":"Chinese Medical Sciences Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9917830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chinese Guideline on the Management of Polypoidal Choroidal Vasculopathy (2022) 中国息肉状脉络膜血管病治疗指南(2022)。
Q2 Medicine Pub Date : 2023-06-01 DOI: 10.24920/004213
You-Xin Cher , Yu-Qing Zhang , Chang-Zheng Chen , Hong Dai , Su-Yan Li , Xiang Ma , Xiao-Dong Sun , Shi-Bo Tang , Yu-Sheng Wang , Wen-Bin Wei , Feng Wen , Ge-Zhi Xu , Wei-Hong Yu , Mei-Xia Zhang , Ming-Wei Zhao , Yang Zhang , Fang Qi , Xun Xu , Xiao-Xin Li

Background

In mainland China, patients with neovascular age-related macular degeneration (nAMD) have approximately an 40% prevalence of polypoidal choroidal vasculopathy (PCV). This disease leads to recurrent retinal pigment epithelium detachment (PED), extensive subretinal or vitreous hemorrhages, and severe vision loss. China has introduced various treatment modalities in the past years and gained comprehensive experience in treating PCV.

Methods

A total of 14 retinal specialists nationwide with expertise in PCV were empaneled to prioritize six questions and address their corresponding outcomes, regarding opinions on inactive PCV, choices of anti-vascular endothelial growth factor (anti-VEGF) monotherapy, photodynamic therapy (PDT) monotherapy or combined therapy, patients with persistent subretinal fluid (SRF) or intraretinal fluid (IRF) after loading dose anti-VEGF, and patients with massive subretinal hemorrhage. An evidence synthesis team conducted systematic reviews, which informed the recommendations that address these questions. This guideline used the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach to assess the certainty of evidence and grade the strengths of recommendations.

Results

The panel proposed the following six conditional recommendations regarding treatment choices. (1) For patients with inactive PCV, we suggest observation over treatment. (2) For treatment-naive PCV patients, we suggest either anti-VEGF monotherapy or combined anti-VEGF and PDT rather than PDT monotherapy. (3) For patients with PCV who plan to initiate combined anti-VEGF and PDT treatment, we suggest later/rescue PDT over initiate PDT. (4) For PCV patients who plan to initiate anti-VEGF monotherapy, we suggest the treat and extend (T&E) regimen rather than the pro re nata (PRN) regimen following three monthly loading doses. (5) For patients with persistent SRF or IRF on optical coherence tomography (OCT) after three monthly anti-VEGF treatments, we suggest proceeding with anti-VEGF treatment rather than observation. (6) For PCV patients with massive subretinal hemorrhage (equal to or more than four optic disc areas) involving the central macula, we suggest surgery (vitrectomy in combination with tissue-plasminogen activator (tPA) intraocular injection and gas tamponade) rather than anti-VEGF monotherapy.

Conclusions

Six evidence-based recommendations support optimal care for PCV patients’ management.

背景在中国大陆,新生血管性年龄相关性黄斑变性(nAMD)患者的息肉状脉络膜血管病(PCV)患病率约为40%。这种疾病会导致复发性视网膜色素上皮脱离(PED)、广泛的视网膜下或玻璃体出血和严重的视力丧失。在过去的几年里,中国引入了各种治疗方式,并在治疗PCV方面获得了全面的经验,光动力疗法(PDT)单药治疗或联合治疗,负载剂量抗VEGF后出现持续性视网膜下液(SRF)或视网膜内液(IRF)的患者,以及大量视网膜下出血的患者。一个证据综合小组进行了系统审查,为解决这些问题的建议提供了信息。本指南使用GRADE(建议、评估、发展和评估的分级)方法来评估证据的确定性,并对建议的强度进行分级。结果专家组就治疗选择提出了以下六项有条件的建议。(1) 对于无活动性PCV的患者,我们建议观察多于治疗。(2) 治疗na?对于PCV患者,我们建议抗VEGF单药治疗或抗VEGF和PDT联合治疗,而不是PDT单药治疗。(3) 对于计划开始联合抗VEGF和PDT治疗的PCV患者,我们建议后期/挽救PDT而不是开始PDT。(4) 对于计划开始抗VEGF单药治疗的PCV患者,我们建议在三个月的负荷剂量后采用治疗和延长(T&E)方案,而不是出生前(PRN)方案。(5) 对于在光学相干断层扫描(OCT)上进行为期三个月的抗VEGF治疗后出现持续性SRF或IRF的患者,我们建议继续进行抗VEGF治疗,而不是观察。(6) 对于涉及中央黄斑的大量视网膜下出血(等于或超过四个视盘区域)的PCV患者,我们建议手术(玻璃体切除联合组织纤溶酶原激活剂(tPA)眼内注射和气体填塞),而不是抗VEGF单药治疗。结论六项循证建议支持PCV患者的最佳护理管理。
{"title":"Chinese Guideline on the Management of Polypoidal Choroidal Vasculopathy (2022)","authors":"You-Xin Cher ,&nbsp;Yu-Qing Zhang ,&nbsp;Chang-Zheng Chen ,&nbsp;Hong Dai ,&nbsp;Su-Yan Li ,&nbsp;Xiang Ma ,&nbsp;Xiao-Dong Sun ,&nbsp;Shi-Bo Tang ,&nbsp;Yu-Sheng Wang ,&nbsp;Wen-Bin Wei ,&nbsp;Feng Wen ,&nbsp;Ge-Zhi Xu ,&nbsp;Wei-Hong Yu ,&nbsp;Mei-Xia Zhang ,&nbsp;Ming-Wei Zhao ,&nbsp;Yang Zhang ,&nbsp;Fang Qi ,&nbsp;Xun Xu ,&nbsp;Xiao-Xin Li","doi":"10.24920/004213","DOIUrl":"10.24920/004213","url":null,"abstract":"<div><h3>Background</h3><p>In mainland China, patients with neovascular age-related macular degeneration (nAMD) have approximately an 40% prevalence of polypoidal choroidal vasculopathy (PCV). This disease leads to recurrent retinal pigment epithelium detachment (PED), extensive subretinal or vitreous hemorrhages, and severe vision loss. China has introduced various treatment modalities in the past years and gained comprehensive experience in treating PCV.</p></div><div><h3>Methods</h3><p>A total of 14 retinal specialists nationwide with expertise in PCV were empaneled to prioritize six questions and address their corresponding outcomes, regarding opinions on inactive PCV, choices of anti-vascular endothelial growth factor (anti-VEGF) monotherapy, photodynamic therapy (PDT) monotherapy or combined therapy, patients with persistent subretinal fluid (SRF) or intraretinal fluid (IRF) after loading dose anti-VEGF, and patients with massive subretinal hemorrhage. An evidence synthesis team conducted systematic reviews, which informed the recommendations that address these questions. This guideline used the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) approach to assess the certainty of evidence and grade the strengths of recommendations.</p></div><div><h3>Results</h3><p>The panel proposed the following six conditional recommendations regarding treatment choices. (1) For patients with inactive PCV, we suggest observation over treatment. (2) For treatment-naive PCV patients, we suggest either anti-VEGF monotherapy or combined anti-VEGF and PDT rather than PDT monotherapy. (3) For patients with PCV who plan to initiate combined anti-VEGF and PDT treatment, we suggest later/rescue PDT over initiate PDT. (4) For PCV patients who plan to initiate anti-VEGF monotherapy, we suggest the treat and extend (T&amp;E) regimen rather than the <em>pro re nata</em> (PRN) regimen following three monthly loading doses. (5) For patients with persistent SRF or IRF on optical coherence tomography (OCT) after three monthly anti-VEGF treatments, we suggest proceeding with anti-VEGF treatment rather than observation. (6) For PCV patients with massive subretinal hemorrhage (equal to or more than four optic disc areas) involving the central macula, we suggest surgery (vitrectomy in combination with tissue-plasminogen activator (tPA) intraocular injection and gas tamponade) rather than anti-VEGF monotherapy.</p></div><div><h3>Conclusions</h3><p>Six evidence-based recommendations support optimal care for PCV patients’ management.</p></div>","PeriodicalId":35615,"journal":{"name":"Chinese Medical Sciences Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9845803","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Chinese Medical Sciences Journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1